COVID-19 Epigenetics and Implications for Public Health

COVID-19 debilitated communities globally in varying complexities and capacities in recent months. The epigenetic changes in the COVID-19 patients were discussed in this article to explore various processes contributing to disease severity and elevation of risk due to infection. The COVID-19 disease is observed to be the most severe in the 65 and-higher-age group with pre-existing chronic conditions. This observational study is a nonexperimental empirical investigation of the outcomes of COVID-19 in different patient groups. Results are promising for conducting clinical trials with intervention groups. To ultimately succeed in disease prevention, researchers and clinicians must integrate epigenetic mechanisms to generate valid prescriptions for global well-being. Percentages of hospitalization, with and without intensive care, in the presence of diseases with increased ACE2 expression, were compared, based on the best available data. Further analysis compared two different age groups, 19-64 and ≥65 years of age.

[1]  Yu-Tang Tung,et al.  Antiplatelet Therapy for Acute Respiratory Distress Syndrome , 2020, Biomedicines.

[2]  Hangyuan Guo,et al.  Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis , 2020, Journal of Infection.

[3]  Z. Dai,et al.  Prevalence and severity of corona virus disease 2019 (COVID-19): A systematic review and meta-analysis , 2020, Journal of Clinical Virology.

[4]  S. Salimi,et al.  COVID-19 and Crosstalk between the Hallmarks of Aging , 2020 .

[5]  J. Zhifeng,et al.  Consistency analysis of COVID-19 nucleic acid tests and the changes of lung CT , 2020, Journal of Clinical Virology.

[6]  Chang Hu,et al.  Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China , 2020, Journal of Clinical Virology.

[7]  S. Maskatia,et al.  COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. , 2020, Hospital pediatrics.

[8]  Q. Lu,et al.  Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients , 2020, Clinical Immunology.

[9]  Emily N. Ussery,et al.  Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[10]  R. Muniyappa,et al.  COVID-19 pandemic, coronaviruses, and diabetes mellitus , 2020, American journal of physiology. Endocrinology and metabolism.

[11]  A. Verma,et al.  COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence? , 2020, JAMA.

[12]  M. Corley,et al.  DNA Methylation Analysis of the COVID-19 Host Cell Receptor, Angiotensin I Converting Enzyme 2 Gene (ACE2) in the Respiratory System Reveal Age and Gender Differences , 2020 .

[13]  Hon-Cheong So,et al.  Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits , 2020, Diabetes Care.

[14]  D. Murdoch,et al.  Clinical course and mortality risk of severe COVID-19 , 2020, The Lancet.

[15]  M. Noman,et al.  Coronavirus Disease 2019 Assosiated Pneumonia in China: Current Status and Future Prospects , 2020 .

[16]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[17]  W. Ko,et al.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges , 2020, International Journal of Antimicrobial Agents.

[18]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[19]  Xingguang Li,et al.  Cross‐species transmission of the newly identified coronavirus 2019‐nCoV , 2020, Journal of Medical Virology.

[20]  B. Stranger,et al.  ImmGen report: sexual dimorphism in the immune system transcriptome , 2019, Nature Communications.

[21]  M. Gwinn,et al.  Next-Generation Sequencing of Infectious Pathogens. , 2019, JAMA.

[22]  Jonathan S Berg,et al.  Finding the Rare Pathogenic Variants in a Human Genome. , 2017, JAMA.

[23]  Alexandra Schäfer,et al.  Epigenetic Landscape during Coronavirus Infection , 2017, Pathogens.

[24]  M. Gwinn,et al.  Integrating Advanced Molecular Technologies into Public Health , 2016, Journal of Clinical Microbiology.

[25]  J. Lieberman,et al.  An Epigenetic Clock Measures Accelerated Aging in Treated HIV Infection. , 2016, Molecular cell.

[26]  G. Omenn,et al.  Epigenetics: relevance and implications for public health. , 2014, Annual review of public health.

[27]  H. Möller,et al.  DNA Methylation Analysis of the Angiotensin Converting Enzyme (ACE) Gene in Major Depression , 2012, PloS one.

[28]  A. Kaparianos,et al.  Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome. , 2011, Current medicinal chemistry.

[29]  M. Matthay,et al.  The acute respiratory distress syndrome: pathogenesis and treatment. , 2011, Annual review of pathology.

[30]  R. Jirtle,et al.  Environmental epigenomics and disease susceptibility , 2007, Nature Reviews Genetics.

[31]  A. Tanigami,et al.  Molecular Cloning, mRNA Expression and Chromosomal Localization of Mouse Angiotensin-converting Enzyme-related Carboxypeptidase (mACE2) , 2002, DNA sequence : the journal of DNA sequencing and mapping.

[32]  P. Coit,et al.  An update on the role of epigenetics in systemic vasculitis , 2018, Current opinion in rheumatology.

[33]  Zehra Sarıgöl,et al.  Epigenetik Değişiklikler ve Beslenme İlişkisi , 2014 .